Volume 32, Number 1—January 2026
Synopsis
Pulmonary Histoplasmosis, Taiwan, 1997–2024
Table 2
Key parameters in study of pulmonary histoplasmosis by host immunity status, Taiwan, 1997–2024*
| Characteristic | All, N = 14 | Immunocompetent, n = 10 | Immunocompromised, n = 4 | p value |
|---|---|---|---|---|
| Mean age, y, + SD |
56.6 + 21.8 |
49.8 + 21.2 |
73.8 ± 12.7 |
0.07 |
| Sex | ||||
| M | 8 (57.1) | 6 (60.0) | 2 (50.0) | 1.00 |
| F |
6 (42.9) |
4 (40.0) |
2 (50.0) |
|
| Any cardinal symptoms |
9 (64.3) |
5 (50.0) |
4 (100.0) |
0.22 |
| Tuberculosis | 2 (14.3) | 1 (10.0) | 1 (25.0) | 0.49 |
| HIV |
0 |
0 |
0 |
NA |
| Travel history |
3 (21.4) |
2 (20.0) |
1 (25.0) |
1.00 |
| Immunosuppression |
4 (28.6) |
|||
| ANC + SD |
4.1 + 2.1 |
4.2 + 1.7 |
3.9 + 3.4 |
1.00 |
| CRP + SD |
4.2 + 3.8 |
3.1 + 4.0 |
5.2 + 4.2 |
0.40 |
| In-hospital death | 1 (7.1) | 0 | 1 (25.0) | 0.29 |
| Complication | 2 (14.3) | 1 (10.0) | 1 (25.0) | 0.51 |
*Values are no. (%) except as indicated. ANC, absolute neutrophil count; CRP, C-reactive protein; NA, not applicable.
Page created: December 06, 2025
Page updated: January 27, 2026
Page reviewed: January 27, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.